RxDoctor Payments Data

Richard Johnston, MD

Urology · Tacoma, WANPI 1477839066

Payments from drug & device makers

$2,582in general payments, 2019–2025

Across 82 payments — averaging $31.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$317
  • Dendreon Pharmaceuticals LLC$265
  • AbbVie$233
  • Boston Scientific$191
  • Myriad Genetic Laboratories, Inc.$186
  • Johnson & Johnson$178
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,49397%
  • Education$893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,582 in reported general payments places this provider in the 55th percentile of 274 urology providers in Washington.

See all urology providers in Washington

Medicare billing

Part B allowed, 2024
$263,719
Medicare patients
410
Services billed
3,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix33$89,269
MyrbetriqMirabegron29$20,674
GemtesaVibegron14$8,187
Trimethoprim67$4,904
Testosterone16$2,424
Tamsulosin Hcl242$2,401
Solifenacin Succinate71$1,912
Finasteride149$1,340
Bethanechol Chloride30$931
Desmopressin Acetate14$764
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen101$596
Oxycodone Hcl31$521
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$484
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim39$310
Tadalafil13$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$160$20,67429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 274 urology providers in Washington.

Other urology in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →